Asset sale Announced
Gilead acquisition of HCXT-2001 (investigational oral IL-23R inhibitor)
Announced Oct 2026 (approx.)
Advisers
HCXT-2001 (investigational oral IL-23R inhibitor)
Target
Not disclosed
Gilead
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- HCXT-2001 (investigational oral IL-23R inhibitor)
- Acquirer
- Gilead
- Seller
- PepStar Therapeutics
- Target based in
- China (unverified)
- Buyer based in
- United States
- Seller based in
- China (unverified)
- Sector
- Pharma
- Tags
- Pharma, Inflammation
In the league tables
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- US WorldMeds acquisition of Orbus Therapeutics Oct 2026 · Pharma
- DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon Sep 2026 · US$316m · Specialty finance and leasing
- Grünenthal acquisition of Stivarga (regorafenib) Sep 2026 · US$433m · Pharma
- Cheplapharm acquisition of portfolio of 20 mature medicines and three manufacturing sites Sep 2026 · Pharma
